Диссертация (1154718), страница 16
Текст из файла (страница 16)
Bates S.M., Jaeschke R., Stevens S.M. [et al.]. Diagnosis of DVT // Chest.2012. № 2 (141). C. e351S–e418S.33. Bautz D.J., Preston G.A., Lionaki S. [et al.]. Antibodies with dual reactivity toplasminogen and complementary PR3 in PR3-ANCA vasculitis. // Journal of theAmerican Society of Nephrology : JASN. 2008. № 12 (19). C.
2421–9.34. Behague I., Poirier O., Nicaud V. [et al.]. Beta fibrinogen gene polymorphismsare associated with plasma fibrinogen and coronary artery disease in patients withmyocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l’Infarctus duMyocarde.
// Circulation. 1996. № 3 (93). C. 440–9.35. Bernardi F., Faioni E.M., Castoldi E. [et al.]. A factor V genetic componentdiffering from factor V R506Q contributes to the activated protein C resistancephenotype. // Blood. 1997. № 4 (90). C. 1552–7.36. Bezemer I.D., Meer F.J.M. van der, Eikenboom J.C.J. [et al.]. The Value ofFamily History as a Risk Indicator for Venous Thrombosis // Archives of InternalMedicine. 2009. № 6 (169). C. 610.11037. Blann A.D. Plasma von Willebrand factor, thrombosis, and the endothelium:the first 30 years.
// Thrombosis and haemostasis. 2006. № 1 (95). C. 49–55.38. Borensztajn K.S., Thüsen J.H. von der, Spek C.A. The role of coagulation inchronic inflammatory disorders: a jack of all trades. // Current pharmaceuticaldesign. 2011. № 1 (17). C. 9–16.39. Bourin M.C., Lindahl U. Glycosaminoglycans and the regulation of bloodcoagulation. // The Biochemical journal. 1993.
C. 313–30.40. Brotman D.J., Deitcher S.R., Lip G.Y.H. [et al.]. Virchow’s triad revisited. //Southern medical journal. 2004. № 2 (97). C. 213–4.41. Brouwer J.-L.P., Bijl M., Veeger N.J.G.M. [et al.]. The contribution ofinherited and acquired thrombophilic defects, alone or combined withantiphospholipid antibodies, to venous and arterial thromboembolism in patientswith systemic lupus erythematosus // Blood. 2004. № 1 (104). C.
143–148.42. Caldeira D., Barra M., Ferreira A. [et al.]. Systematic review with metaanalysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonistoral anticoagulants // Alimentary Pharmacology & Therapeutics. 2015. № 11–12(42). C. 1239–1249.43. Caldeira D., Rodrigues F.B., Barra M. [et al.]. Non-vitamin K antagonist oralanticoagulants and major bleeding-related fatality in patients with atrial fibrillationand venous thromboembolism: a systematic review and meta-analysis // Heart.2015.
№ 15 (101). C. 1204–1211.44. Carrier M., H E., Wells P.S. [et al.]. Systematic Review: Case-Fatality Rates ofRecurrent Venous Thromboembolism and Major Bleeding Events Among PatientsTreated for Venous Thromboembolism // Annals of Internal Medicine. 2010. № 9(152). C. 578.45. Cattaneo M. Hyperhomocysteinemia: a risk factor for arterial and venousthrombotic disease. // International journal of clinical & laboratory research. 1997.№ 3 (27). C. 139–44.46. Catto A.J., Kohler H.P., Coore J. [et al.]. Association of a commonpolymorphism in the factor XIII gene with venous thrombosis. // Blood. 1999.
№ 3111(93). C. 906–8.47. Chamorro A.-J., Marcos M., Hernández-García I. [et al.]. Association of allelicvariants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductasewith thrombosis or ocular involvement in Behçet’s disease: A systematic reviewand meta-analysis // Autoimmunity Reviews. 2013. № 5 (12). C. 607–616.48.
Chung M.-C., Jorgensen S.C., Popova T.G. [et al.]. Neutrophil elastase andsyndecan shedding contribute to antithrombin depletion in murine anthrax. //FEMS immunology and medical microbiology. 2008. № 3 (54). C. 309–18.49. Curran J.M., Evans A., Arveiler D. [et al.]. The alpha fibrinogen T/A312polymorphism in the ECTIM study.
// Thrombosis and haemostasis. 1998. № 5(79). C. 1057–8.50. Cushman M., Folsom A.R., Wang L. [et al.]. Fibrin fragment D-dimer and therisk of future venous thrombosis // Blood. 2003. № 4 (101). C. 1243–1248.51. Cushman M., Tsai A.W., White R.H. [et al.]. Deep vein thrombosis andpulmonary embolism in two cohorts: the longitudinal investigation ofthromboembolism etiology // The American Journal of Medicine. 2004. № 1 (117).C.
19–25.52. D’Argenio G., Cosenza V., Riegler G. [et al.]. Serum transglutaminasecorrelates with endoscopic and histopathologic grading in patients with ulcerativecolitis. // Digestive diseases and sciences. 2001. № 3 (46). C. 649–57.53. Dahlbäck B. Coagulation and inflammation--close allies in health and disease.// Seminars in immunopathology. 2012. № 1 (34). C. 1–3.54.
Dahlbäck B., Carlsson M., Svensson P.J. Familial thrombophilia due to apreviously unrecognized mechanism characterized by poor anticoagulant responseto activated protein C: prediction of a cofactor to activated protein C. //Proceedings of the National Academy of Sciences of the United States of America.1993. № 3 (90).
C. 1004–8.55. Demirci F.Y.K., Dressen A.S., Kammerer C.M. [et al.]. Functionalpolymorphisms of the coagulation factor II gene (F2) and susceptibility to systemiclupus erythematosus. // The Journal of rheumatology. 2011. № 4 (38). C. 652–7.11256. Dongen C.J.J. van, Vink R., Hutten B.A. [et al.]. The Incidence of RecurrentVenous Thromboembolism After Treatment With Vitamin K Antagonists inRelation to Time Since First Event // Archives of Internal Medicine. 2003.
№ 11(163). C. 1285.57. Faioni E.M., Franchi F., Bucciarelli P. [et al.]. Coinheritance of the HR2haplotype in the factor V gene confers an increased risk of venousthromboembolism to carriers of factor V R506Q (factor V Leiden). // Blood. 1999.№ 9 (94). C. 3062–6.58. Faurschou M., Obel N., Baslund B. High risk of pulmonary embolism and deepvenous thrombosis but not of stroke in granulomatosis with polyangiitis(Wegener’s). // Arthritis care & research. 2014.
№ 12 (66). C. 1910–4.59. Floyd C.N., Mustafa A., Ferro A. The PlA1/A2 Polymorphism of GlycoproteinIIIa as a Risk Factor for Myocardial Infarction: A Meta-Analysis // PLoS ONE.2014. № 7 (9). C. e101518.60. Franco R.F., Reitsma P.H., Lourenço D. [et al.]. Factor XIII Val34Leu is agenetic factor involved in the etiology of venous thrombosis. // Thrombosis andhaemostasis. 1999.
№ 5 (81). C. 676–9.61. Frosst P., Blom H.J., Milos R. [et al.]. A candidate genetic risk factor forvascular disease: a common mutation in methylenetetrahydrofolate reductase //Nature Genetics. 1995. № 1 (10). C. 111–113.62. Galanaud J.-P., Sevestre M.-A., Genty C. [et al.]. Incidence and predictors ofvenous thromboembolism recurrence after a first isolated distal deep veinthrombosis. // Journal of thrombosis and haemostasis : JTH. 2014.
№ 4 (12). C.436–43.63. Gardemann A., Schwartz O., Haberbosch W. [et al.]. Positive association of thebeta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increasein fibrinogen concentration during acute phase reaction but not to coronary arterydisease and myocardial infarction. // Thrombosis and haemostasis. 1997. № 6 (77).C.
1120–6.64. Gong R., Liu Z., Li L. Epistatic effect of plasminogen activator inhibitor 1 and113β-Fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis:Interaction with environmental/clinical factors // Arthritis & Rheumatism. 2007. №5 (56). C. 1608–1617.65. Gu L., Wu G., Su L.
[et al.]. Genetic polymorphism of β-fibrinogen gene455G/A can contribute to the risk of ischemic stroke // Neurological Sciences.2014. № 2 (35). C. 151–161.66. Gushiken F.C., Han H., Li J. [et al.]. Abnormal platelet function in C3deficient mice. // Journal of thrombosis and haemostasis : JTH. 2009. № 5 (7). C.865–70.67. Hansson P.O., Sörbo J., Eriksson H. Recurrent venous thromboembolism afterdeep vein thrombosis: incidence and risk factors. // Archives of internal medicine.2000.
№ 6 (160). C. 769–74.68. Hansson P.O., Welin L., Tibblin G. [et al.]. Deep vein thrombosis andpulmonary embolism in the general population. «The Study of Men Born in 1913».// Archives of internal medicine. № 15 (157). C. 1665–70.69. Hao J., Wang C., Gou S.-J.
[et al.]. The association between anti-plasminogenantibodies and disease activity in ANCA-associated vasculitis. // Rheumatology(Oxford, England). 2014. № 2 (53). C. 300–6.70. Heinrich J., Balleisen L., Schulte H. [et al.]. Fibrinogen and factor VII in theprediction of coronary risk. Results from the PROCAM study in healthy men. //Arteriosclerosis and thrombosis : a journal of vascular biology. 1994. № 1 (14). C.54–9.71. Heit J.A. Venous thromboembolism: disease burden, outcomes and risk factors// Journal of Thrombosis and Haemostasis. 2005. № 8 (3).
C. 1611–1617.72. Heit J.A. Estimating the Incidence of Symptomatic Postoperative VenousThromboembolism // JAMA. 2012. № 3 (307). C. 306–7.73. Heit J.A., Mohr D.N., Silverstein M.D. [et al.]. Predictors of recurrence afterdeep vein thrombosis and pulmonary embolism: a population-based cohort study.// Archives of internal medicine. 2000. № 6 (160). C. 761–8.74. Heit J.A., Silverstein M.D., Mohr D.N. [et al.].
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
